In contrast, subgroup analysis of MRC AML 12 trial failed to show any benefit from the addition of ATRA to intensive chemotherapy in general and specifically in patients with NPM1 mutations with or without FLT3-ITD mutations in terms of response rate (P = 0.6 and 0.1, respectively), relapse (P = 0.8 and 0.2, respectively), and OS (P = 0.2 and 0.3, respectively) (18). This evidence concerns the gene FLT3 and acute myeloid leukemia.